| 9.19 -0.52 (-5.36%) | 07-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 13.65  |
1-year : | 15.94 |
| Resists | First : | 11.68 |
Second : | 13.65 |
| Pivot price | 6.96 |
|||
| Supports | First : | 7.44 |
Second : | 4.82 |
| MAs | MA(5) : | 8.11 |
MA(20) : | 6.66 |
| MA(100) : | 4.43 |
MA(250) : | 0 | |
| MACD | MACD : | 0.8 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 83 |
| RSI | RSI(14): 74.2 |
|||
| 52-week | High : | 26.5 | Low : | 2.56 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TTRX ] has closed below upper band by 0.6%. Bollinger Bands are 287.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 11.7 - 11.76 | 11.76 - 11.8 |
| Low: | 8.9 - 8.94 | 8.94 - 8.98 |
| Close: | 9.11 - 9.19 | 9.19 - 9.26 |
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
Wed, 08 Jul 2026
Turn Therapeutics Reaches US$229m Market Cap Benefiting Insider Stock Buying - Moomoo
Tue, 07 Jul 2026
Turn Therapeutics (TTRX) Study update Summary - Quartr
Tue, 07 Jul 2026
Why Is Turn Therapeutics Stock Trading Higher Today? - Benzinga
Tue, 07 Jul 2026
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Tue, 07 Jul 2026
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
Tue, 07 Jul 2026
Turn Therapeutics (TTRX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 30 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 63.7 (%) |
| Held by Institutions | 1.7 (%) |
| Shares Short | 64 (K) |
| Shares Short P.Month | 65 (K) |
| EPS | -0.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | -129.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.04 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -70.7 |
| PEG Ratio | 0 |
| Price to Book value | 45.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -70.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|